Filing Flows › CG Oncology (CGON) › Q1 2025
CG Oncology (CGON) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
CG Oncology (CGON) reported revenue of $52K for the first quarter 2025 (Q1 2025), -90% from a year earlier and -89% from the quarter before.
CG Oncology, Q1 2025: revenue $52K (-90% year over year), net loss $34.5M, operating cash flow −$29.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $52K | -89% | -90% |
| Operating profit | −$42.2M | — | — |
| Net earnings | −$34.5M | — | — |
| Operating cash flow | −$29.3M | — | — |
What changed
Revenue was $52K in Q1 2025, down 90% year over year and down 89% from the previous quarter.
Operating costs exceeded revenue by $42.2M, an operating margin of -81161.5%. Total costs grew 84% against a revenue fall of 90%. The fastest-growing cost line was General & admin (+156%). The quarter ended with a net loss of $34.5M, wider than the previous quarter's $31.8M loss. Non-operating items added $7.8M, -23% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$29.3M. Non-cash charges added back $24K of depreciation and amortization and $5.2M of share-based compensation. Capital expenditures of $16K exceeded it, leaving free cash flow of −$29.3M.
Questions
What was CG Oncology's revenue in the first quarter 2025?
CG Oncology (CGON) reported revenue of $52K for the first quarter 2025 (Q1 2025), -90% from a year earlier and -89% from the quarter before.
Source: CG Oncology 10-Q on SEC EDGAR.